Compare IDEXX Laboratories, Inc. (IDXX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nuscale Power Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Nuscale Power Corporation trades at $7.18 (market cap $3.00B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13.5× Nuscale Power Corporation's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 43,143,109). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Nuscale Power Corporation for 29 Days on average.
| IDXX | SMR | |
|---|---|---|
Market Cap | $40.43B | $3.00B |
Volume | 692,164 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $766.68 | $53.43 |
52-Week Low | $504.70 | $7.32 |
Typical Hold Time | 46 Days | 29 Days |
Enterprise Value | $41.32B | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
SMR trades at $7.145, down 6.84% on the day, reflecting ongoing investor concerns. The stock is technically bearish with moving averages signaling a downtrend, while fundamentals show severe losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Recent news highlights a Pomerantz law firm investigation into the company, adding to headwinds despite some analyst optimism.
The outlook remains high-risk; while 50% of analysts rate it a buy with a $11.25 consensus target, persistent losses, cash burn, and competitive pressures in the nuclear SMR space pose significant challenges. Upside depends on successful commercialization, but current financials and sentiment suggest caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
